← Back to Clinical Trials
RecruitingNCT05388682
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
◆ AI Clinical Summary
Plain-language summary for patients
Trial Parameters
ConditionTakayasu Arteritis With Pulmonary Artery Involvement
SponsorChinese Pulmonary Vascular Disease Research Group
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment200
SexALL
Min AgeN/A
Max AgeN/A
Start Date2014-01-19
Completion2042-12-31
All Conditions
Interventions
Percutaneous transluminal pulmonary angioplasty
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement
Eligibility Criteria
Inclusion Criteria: * patients diagnosed with Takayasu arteries with pulmonary arteries involvement Exclusion Criteria: * Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology